Floatz logo

CITALOPRAM

Relapsing-remitting Multiple Sclerosis

Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

80 Active assets in the Relapsing-remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB

View all 50 →

Same molecule, other indications

CITALOPRAM is also rated in:

Bipolar I DisorderDormant
BBB
Indicative ·
77 / 100
View asset →
bipolar disorderDormant
BBB
Indicative ·
74 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →